Regeneron Pharmaceuticals, Inc.

(NASDAQ Global Select)
Back to all articles
Slightly Bullish +25

Pictet Asset Management Holding SA Sells 30,616 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

AI-generated analysis

πŸ“‰ Pictet Asset Management Holding SA sold 30,616 shares of Regeneron in Q1, reducing its stake by 8.3% to a remaining value of roughly $258.4 million.

πŸ“ˆ WPG Advisers LLC significantly increased its position by 312.5% in Q4, now holding 33 shares valued at approximately $25,000.

πŸ’° Regeneron reported Q1 EPS of $9.47, beating the $8.91 consensus estimate, with revenue rising 19% year-over-year to $3.61 billion.

πŸ“Š The stock trades at a P/E ratio of 15.42 and a market capitalization of $66.91 billion as of the latest trading session.

πŸ’΅ Regeneron declared a quarterly dividend of $0.94 per share, paid on June 4th to shareholders of record on May 20th.

πŸ“‰ Canaccord Genuity lowered its price target from $1,057 to $875 while reaffirming a buy rating on the stock.

πŸ“‰ Citigroup downgraded Regeneron from buy to neutral and reduced its price objective from $900 to $700.

πŸ“‰ Leerink Partners cut its price target to $641, down from $792, while maintaining a market perform rating.

🏦 Institutional ownership stands at 83.31%, with company insiders owning approximately 6.97% of the total shares outstanding.

πŸ“‰ The stock is currently trading at $632.90, which is below its 50-day moving average of $663.51 and 200-day moving average of $728.45.

Bullish Signals
  • Regeneron delivered a solid earnings beat with Q1 EPS of $9.47 versus the expected $8.91, demonstrating strong operational performance.
  • Revenue grew 19% year-over-year to $3.61 billion, significantly exceeding analyst estimates of $3.48 billion.
  • The company maintains a healthy balance sheet with a current ratio of 3.57 and a debt-to-equity ratio of only 0.06.
  • Institutional investors like WPG Advisers LLC are increasing their positions, suggesting confidence in the long-term outlook despite recent selling by others.
  • Regeneron has a history of paying dividends, recently issuing a $0.94 quarterly dividend with a payout ratio of 9.16%.
Risk Factors
  • Several major analysts have recently downgraded their price targets or ratings, citing concerns that may be weighing on the stock's near-term momentum.
  • The stock is trading below its key moving averages, currently at $632.90 versus a 50-day average of $663.51 and a 200-day average of $728.45.
  • Canaccord Genuity reduced its price target significantly from $1,057 to $875, indicating potential valuation concerns among sell-side analysts.
  • Citigroup downgraded the stock to neutral with a lower price objective of $700, reflecting a more cautious stance on the company's prospects.
Full Analysis
Pictet Asset Management Holding SA reduced its stake in Regeneron Pharmaceuticals, Inc. (REGN) by 8.3% in the first quarter, selling 30,616 shares and retaining a position valued at approximately $258.4 million. While Pictet lowered its exposure, several other institutional investors increased their holdings during the fourth quarter, including WPG Advisers LLC which lifted its position by 312.5%, indicating mixed but active institutional interest in the biopharmaceutical company. Regeneron reported strong first-quarter financial results that exceeded analyst expectations, with earnings per share of $9.47 against a consensus of $8.91 and revenue reaching $3.61 billion, a 19% year-over-year increase. The company maintains a robust balance sheet with a market capitalization of $66.91 billion, a P/E ratio of 15.42, and recently declared a quarterly dividend of $0.94 per share, reflecting its continued profitability and cash generation capabilities. Despite the solid earnings beat, Wall Street sentiment remains cautious with several major firms downgrading their ratings or price targets for REGN shares in recent weeks. Canaccord Genuity lowered its target to $875 while maintaining a buy rating, Citigroup cut its objective to $700 and switched to neutral, and Leerink Partners reduced its target to $641, contributing to a consensus Moderate Buy rating with an average price target of $792.65.